Benefits: Supports significant weight loss by reducing appetite and increasing energy expenditure
To view or add a comment, sign in Beyond Weight Loss: The New Era of Obesity Medicine with Triple-Agonists and Complication-Centric Care The landscape of obesity medicine is transforming at an unprecedented pace
Generally, single use will not lead to hypoglycemia, but if combined with sulfonylureas or insulin, attention should be paid to prevent hypoglycemia (142)
Conclusion When counseling patients in clinical decision-making, managing expectations is essential
More than 30 million Americans will be on GLP-1 treatment in 2030, according to an estimate from JP Morgan
GLP-1 Drugs: Demand Surges in a Long-Established Market The market for GLP-1 drugs is projected to reach $180 billion in 2034, according to Morningstar Equity Research